Project Page

Back to search results

Assess suitability of multiplexing

Prof Ralph Martins, Dr Andrea C. Wilson
Research Centre DCRC Early Diagnosis and Prevention
Partner Institution ECU
Project Description

The Luminex xMAP bioassay technology revolves around the traditional sandwich ELISA assay.

This assay requires the use of two complimentary antibodies for the detection of a single biomarker which insures specific detection of the biomarker. There are several barriers in the development stages that will need to be addressed for a successful Luminex assay:

Firstly, the successful conjugation of a selected antibody on to the beads;

Secondly, the sourcing of available antibodies that will specifically detect the same protein/peptide without interference with each other.

In addition, a compatible sample diluent is required for sample dilution which could affect the sensitivity of the resultant assay. Once the technique is successful for the detection of one biomarker, testing will be conducted for the simultaneous detection of all candidate biomarkers, namely  isoforms, apoE and IDE.

The successful plexing of two or more candidate biomarkers will provide proof of concept towards the future development of an optimal AD biomarker panel assay (or assays) for AD diagnostic, prediction and/or monitoring purposes. The benefits of the multiplex assay technique will firstly, save sample required, secondly save time and thus, the savings in the end cost of the diagnosis.

Project Portfolio

Back to search results